-
Founded in:
1998-05-04 -
Country:
China -
Address:
Bianque Road, Tangyin Industrial Cluster Zone, Anyang City -
Tax NO.:
91410523706582188B -
Registered Funds:
80 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Potassium chloride |
Potassium is the main cation in cells, with a concentration of 150-160 mmol/L, while the main cation outside cells is sodium ions, and the serum potassium concentration is only 3.5-5.0 mmol/L. The body mainly relies on Na+-K+ ATPase on the cell membrane to maintain the difference in K+ and Na+ concentrations inside and outside cells. The acid-base balance in the body has an impact on potassium metabolism. For example, when acidosis occurs, H+ enters the cell. In order to maintain the potential difference inside and outside the cell, K+ is released outside the cell, causing or aggravating hyperkalemia. Metabolic disorders can also affect acid-base balance. The normal potassium ion concentration and concentration difference inside and outside cells are closely related to certain functions of cells, such as carbohydrate metabolism, glycogen storage and protein metabolism, excitability and conductivity of nerves and muscles including myocardium, etc.
More
Potassium is the main cation in cells, with a concentration of 150-160 mmol/L, while the main cation outside cells is sodium ions, and the serum potassium concentration is only 3.5-5.0 mmol/L. The body mainly relies on Na+-K+ ATPase on the cell membrane to maintain the difference in K+ and Na+ concentrations inside and outside cells. The acid-base balance in the body has an impact on potassium metabolism. For example, when acidosis occurs, H+ enters the cell. In order to maintain the potential difference inside and outside the cell, K+ is released outside the cell, causing or aggravating hyperkalemia. Metabolic disorders can also affect acid-base balance. The normal potassium ion concentration and concentration difference inside and outside cells are closely related to certain functions of cells, such as carbohydrate metabolism, glycogen storage and protein metabolism, excitability and conductivity of nerves and muscles including myocardium, etc. |
7447-40-7 | 39 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| (+/-)-10-CAMPHORSULFONIC ACID SODIUM SALT |
This product is a respiratory stimulant that can stimulate the respiratory center and excite breathing.
More
This product is a respiratory stimulant that can stimulate the respiratory center and excite breathing. |
34850-66-3 | 1 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Lidocaine hydrochloride |
This product is an amide local anesthetic. After blood absorption or intravenous administration, it has obvious biphasic effects of excitation and inhibition on the central nervous system, and there may be no precursor excitation. When the blood concentration is low, analgesia and drowsiness occur, and the pain threshold increases; with increasing doses, the effect or toxicity increases, and it has an anticonvulsant effect at sub-toxic blood concentrations; convulsions may occur when the blood concentration exceeds 5μg·ml-1. At low doses, this product can promote the outflow of K in myocardial cells, reduce myocardial autonomy, and have an anti-ventricular arrhythmia effect; at therapeutic doses, it has no obvious effect on the electrical activity of myocardial cells, atrioventricular conduction, and myocardial contraction; further increases in blood concentrations can cause a slowing of heart conduction velocity, atrioventricular conduction block, inhibition of myocardial contractility, and a decrease in cardiac output.
More
This product is an amide local anesthetic. After blood absorption or intravenous administration, it has obvious biphasic effects of excitation and inhibition on the central nervous system, and there may be no precursor excitation. When the blood concentration is low, analgesia and drowsiness occur, and the pain threshold increases; with increasing doses, the effect or toxicity increases, and it has an anticonvulsant effect at sub-toxic blood concentrations; convulsions may occur when the blood concentration exceeds 5μg·ml-1. At low doses, this product can promote the outflow of K in myocardial cells, reduce myocardial autonomy, and have an anti-ventricular arrhythmia effect; at therapeutic doses, it has no obvious effect on the electrical activity of myocardial cells, atrioventricular conduction, and myocardial contraction; further increases in blood concentrations can cause a slowing of heart conduction velocity, atrioventricular conduction block, inhibition of myocardial contractility, and a decrease in cardiac output. |
6108-05-0 | 46 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Sodium bicarbonate |
1. Treat metabolic acidosis. This product increases the concentration of carbonate in plasma and neutralizes hydrogen ions, thereby correcting acidosis. 2. Alkalinize urine. As the pH value increases after the concentration of bicarbonate in urine increases, uric acid, sulfonamide drugs and hemoglobin are not easy to form crystals or aggregate in urine. 3. Antacid. Oral administration can quickly neutralize or buffer gastric acid without directly affecting gastric acid secretion. Therefore, the pH in the stomach increases rapidly to relieve the symptoms caused by high gastric acid.
More
1. Treat metabolic acidosis. This product increases the concentration of carbonate in plasma and neutralizes hydrogen ions, thereby correcting acidosis. 2. Alkalinize urine. As the pH value increases after the concentration of bicarbonate in urine increases, uric acid, sulfonamide drugs and hemoglobin are not easy to form crystals or aggregate in urine. 3. Antacid. Oral administration can quickly neutralize or buffer gastric acid without directly affecting gastric acid secretion. Therefore, the pH in the stomach increases rapidly to relieve the symptoms caused by high gastric acid. |
144-55-8 | 47 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Diclofenac sodium |
Extract from the above information
More
Extract from the above information |
15307-79-6 | 55 |